Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1999 Nov;58(Suppl 1):I129–I130. doi: 10.1136/ard.58.2008.i129

Access to disease modifying treatments for rheumatoid arthritis patients

D FURST, F BREEDVELD, G BURMESTER, L CROFFORD, P EMERY, M FELDMAN, J KALDEN, A KAVANAUGH, E KEYSTONE, P LIPSKY, R MAINI, L MORELAND, J SMOLEN, L VAN DE PUTTE, T VISCHER, M WEINBLATT, M WEISSMAN
PMCID: PMC1766569  PMID: 10577989

Full Text

The Full Text of this article is available as a PDF (45.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  2. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  3. Feldmann M., Elliott M. J., Woody J. N., Maini R. N. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol. 1997;64:283–350. doi: 10.1016/s0065-2776(08)60891-3. [DOI] [PubMed] [Google Scholar]
  4. Fenner H. Immunpharmakologisches Profil und therapeutische Perspektiven von anti-TNF alpha-Therapien. Z Rheumatol. 1998 Oct;57(5):294–297. doi: 10.1007/s003930050114. [DOI] [PubMed] [Google Scholar]
  5. Goldenberg M. M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999 Jan;21(1):75–2. doi: 10.1016/S0149-2918(00)88269-7. [DOI] [PubMed] [Google Scholar]
  6. Kalden-Nemeth D., Grebmeier J., Antoni C., Manger B., Wolf F., Kalden J. R. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int. 1997;16(6):249–255. doi: 10.1007/BF01375657. [DOI] [PubMed] [Google Scholar]
  7. Kavanaugh A. F. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):593–614. doi: 10.1016/s0889-857x(05)70028-4. [DOI] [PubMed] [Google Scholar]
  8. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Davis D., Macfarlane J. D., Antoni C., Leeb B., Elliott M. J., Woody J. N. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998 Sep;41(9):1552–1563. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  9. Maini R. N., Elliott M. J., Brennan F. M., Williams R. O., Chu C. Q., Paleolog E., Charles P. J., Taylor P. C., Feldmann M. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 1995 Apr;144:195–223. doi: 10.1111/j.1600-065x.1995.tb00070.x. [DOI] [PubMed] [Google Scholar]
  10. Maini R. N., Elliott M. J., Charles P. J., Feldmann M. Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunopathol. 1994;16(2-3):327–336. doi: 10.1007/BF00197526. [DOI] [PubMed] [Google Scholar]
  11. Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
  12. Moreland L. W. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug;24(3):579–591. doi: 10.1016/s0889-857x(05)70027-2. [DOI] [PubMed] [Google Scholar]
  13. Paleolog E. M., Young S., Stark A. C., McCloskey R. V., Feldmann M., Maini R. N. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998 Jul;41(7):1258–1265. doi: 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1. [DOI] [PubMed] [Google Scholar]
  14. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES